Patent application number | Description | Published |
20080241190 | VACCINATION OF HORSES AGAINST LAWSONIA INTRACELLULARIS - The present invention is broadly concerned with vaccination of horses against proliferative enteritis, preferably equine proliferative ileitis, which is caused by an obligate intracellular bacterium Lawsonia Intracellularis (L. intracellularis). Specifically, the invention provides for a method of providing immune protection against L. intracellularis by vaccinating horses, preferably foals starting from one (1) week of age. Preferably the foals are vaccinated with about 4.9 log 10 to about 6.9 log 10 of a live modified L. intracellularis bacteria per dose. | 10-02-2008 |
20080312210 | USE OF A SPECIFIC CYCLIC AMINE DERIVATIVE OR THE PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF FOR THE TREATMENT OR PREVENTION OF HEART FAILURE - The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment of heart failure of any aetiology. | 12-18-2008 |
20090082282 | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure - The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca | 03-26-2009 |
20100035889 | Use of PDE III Inhibitors For The Treatment of Asymptomatic (Occult) Heart Failure - The invention relates to the use of a phosphodiesterase type III (PDE III) inhibitor or Ca | 02-11-2010 |
20110251208 | PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY - The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca | 10-13-2011 |
20120231027 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 09-13-2012 |
20130203690 | PDE III INHIBITORS FOR TREATMENT OF ASYMPTOMATIC HEART FAILURE - Phosphodiesterase type III (PDE III) inhibitor or a “Ca | 08-08-2013 |
20130317008 | Use of a Specific Cyclic Amine Derivative or the Pharmaceutically Acceptable Salts Thereof for the Treatment or Prevention of Heart Failure - The present invention provides the use in a pharmaceutical composition of a specific cyclic amine derivative, or its pharmaceutically acceptable salts, for the treatment or prevention of heart failure of any aetiology. | 11-28-2013 |
20140050755 | NOVEL H5 PROTEINS, NUCLEIC ACID MOLECULES AND VECTORS ENCODING FOR THOSE, AND THEIR MEDICINAL USE - The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals. | 02-20-2014 |
20140155338 | USE OF PDE III INHIBITORS FOR THE REDUCTION OF HEART SIZE IN MAMMALS SUFFERING FROM HEART FAILURE - A phosphodiesterase type III (PDE III) inhibitor or Ca | 06-05-2014 |